Annual Securities Report — FY2025
What Astellas Pharma Inc. reported for the period from 2025-04-01 to 2026-03-31.
Filed 2026-06-16View the original on EDINET
How much it says
48Typical
What moved here
27named for the first time
Its own wording
46terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
The filing reports performance and financial condition for the fiscal year (1 April 2025 to 31 March 2026), including revenue, core operating profit, profit for the year and cash flows. It also describes the strategic targets and performance indicators of Management Plan 2026, as well as sustainability and risk management. Disclosures on the progress of priority strategic products, technology in-licensing agreements and shareholder returns, including the dividend-growth policy, have been updated.
Komori's summary of this document, not the document's own words.48Typical
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
45
Typical
16
Almost nothing
62
Detailed
25
Almost nothing
100
Very detailed
0
Almost nothing
31
Thin
100
Very detailed
13
Almost nothing
55
Typical
50
Typical
R&D spend3,148億円Money spent making new things.
Cash left overNot disclosedThis document does not carry the figure.
Spent on equipment493億円Plants, machines — things meant to last.
Employees4,081Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.